Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53

Oncogene

Volumn 22, Issue 19, 2003, Pages 2960-2966

  Bristow, Robert G ^a,b   Peacock, James ^a   Jang, Anne ^a   Kim, John ^a   Hill, Richard P ^a   Benchimol, Samuel ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Gain of function; MEF; Metastasis; p53; Sensitivity; Transformation

Indexed keywords

CISPLATIN; METHOTREXATE; MUTANT PROTEIN; PROTEIN P53;

ALLELE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANCER THERAPY; CELL TRANSFORMATION; CHEMOSENSITIVITY; CLONE; DNA DAMAGE; ERYTHROLEUKEMIA CELL; FIBROBLAST; GENETIC TRANSFECTION; GROWTH RATE; IONIZING RADIATION; METASTASIS; MOUSE; NONHUMAN; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIVITY; TUMOR CELL; TUMOR GROWTH; ULTRAVIOLET RADIATION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA DAMAGE; HUMANS; MICE; MUTATION; NEOPLASM METASTASIS; NEOPLASMS; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 0038021147     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206405     Document Type: Article

References (49)

1. Albor A, Kaku S and Kulesz-Martin M. (1998). Cancer Res., 58, 2091-2094.
2. Bernstein C, Bernstein H, Payne CM and Garewal H. (2002). Mutat. Res., 511, 145-178.
3. Blandino G, Levine AJ and Oren M. (1999). Oncogene, 18, 477-485.
4. Bristow RG, Benchimol S and Hill RP. (1996). Radiother. Oncol., 40, 197-223.
5. Bristow RG, Hu Q, Jang A, Chung S, Peacock J, Benchimol S and Hill R. (1998). Oncogene, 16, 1789-1802.
6. Bullock AN, Henckel J and Fersht AR. (2000). Oncogene, 19, 1245-1256.
7. Cadwell C and Zambetti GP. (2001). Gene, 277, 15-30.
8. Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J and Roninson IB. (1999). Oncogene, 18, 4808-4818.
9. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C and Levine AJ. (1993). Nat. Genet., 4, 42-46.
10. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS and Bradley A. (1992). Nature, 356, 215-221.
11. Foster BA, Coffey HA, Morin MJ and Rastinejad F. (1999). Science, 286, 2507-2510.
12. Gaiddon C, Lokshin M, Ahn J, Zhang T and Prives C. (2001). Mol. Cell. Biol., 21, 1874-1887.
13. Gangopadhyay S, Jalali F, Reda D, Peacock J, Bristow RG and Benchimol S. (2002). Exp. Cell Res., 275, 122-131.
14. Grant SW, Kyshtoobayeva AS, Kurosaki T, Jakowatz J and Fruehauf JP. (1998). Cancer Detect. Prev., 22, 185-194.
15. Gualberto A, Aldape K, Kozakiewicz K and Tlsty TD. (1998). Proc. Natl. Acad. Sci. USA, 95, 5166-5171.
16. Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA, Bradley A and Donehower LA. (1993). Oncogene, 8, 2457-2467.
17. Hoeijmakers JH. (2001). Nature, 411, 366-374.
18. Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J and Haas M. (1994). Am. J. Pathol., 145, 702-714.
19. Illidge TM, Cragg MS, Fringes B, Olive P and Erenpreisa JA. (2000). Cell. Biol. Int., 24, 621-633.
20. Iwamoto KS, Mizuno T, Ito T, Tsuyama N, Kyoizumi S and Seyama T. (1996). Cancer Res., 56, 3862-3865.
21. Iwanaga Y and Jeang KT. (2002). Cancer Res., 62, 2618-2624.
22. Kieser A, Weich HA, Brandner G, Marme D and Kolch W. (1994). Oncogene, 9, 963-969.
23. Kirsch DG and Kastan MB. (1998). J. Clin. Oncol., 16, 3158-3168.
24. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M and Rotter V. (1998). Oncogene, 16, 3269-3277.
25. Lin Y and Benchimol S. (1995). Mol. Cell. Biol., 15, 6045-6054.
26. Liu MC and Gelmann EP. (2002). Semin. Oncol., 29, 246-257.
27. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK and Lozano G. (2000). Proc. Natl. Acad. Sci. USA, 97, 4174-4179.
28. Melchior F and Hengst L. (2002). Cell Cycle, 1, 245-249.
29. Monti P, Campomenosi P, Ciribilli Y, Iannone R, Inga A, Abbondandolo A, Resnick MA and Fronza G. (2002). Oncogene, 21, 1641-1648.
30. Morris SM. (2002). Mutat. Res., 511, 45-62.
31. Offer H, Milyavsky M, Erez N, Matas D, Zurer I, Harris CC and Rotter, V. (2001). Oncogene, 20, 581-589.
32. Peacock JW, Chung S, Bristow RG, Hill RP and Benchimol S. (1995). Mol. Cell. Biol., 15, 1446-1454.
33. Powell SN, DeFrank JS, Connell P, Eogan M, Preffer F, Dombkowski D, Tang W and Friend S. (1995). Cancer Res., 55, 1643-1648.
34. Pugacheva EN, Ivanov AV, Kravchenko JE, Kopnin BP, Levine AJ and Chumakov PM. (2002). Oncogene, 21, 4595-4600.
35. Roth JA, Grammer SF, Swisher SG, Komaki R, Nemunaitis J, Merritt J and Meyn RE. (2001). Acta Oncol., 40, 739-744.
36. Selivanova G. (2001). Curr. Opin. Invest. Drugs, 2, 1136-1141.
37. Sharpless NE and DePinho RA. (2002). Cell, 110, 9-12.
38. Sigal A and Rotter V. (2000). Cancer Res., 60, 6788-6793.
39. Slichenmyer WJ, Nelson WG, Slebos RJ and Kastan MB. (1993). Cancer Res., 53, 4164-4168.
40. Slingerland JM, Jenkins JR and Benchimol S. (1993). EMBO J. 12, 1029-1037.
41. Smith ML and Seo YR. (2002). Mutagenesis, 17, 149-156.
42. Soussi T and Beroud C. (2001). Nat. Rev. Cancer, 1, 233-240.
43. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M and Blandino G. (2002). J. Biol. Chem., 13, 13.
44. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J and el-Deiry WS. (2002). Cancer Biol. Ther., 1, 47-55.
45. Tang W, Willers H and Powell SN. (1999). Cancer Res., 59, 2562-2565.
46. Tannock IF and Lee C. (2001). Br. J. Cancer, 84, 100-105.
47. van Oijen MG and Slootweg PJ. (2000). Clin. Cancer Res., 6, 2138-2145.
48. Wahl GM and Carr AM. (2001). Nat. Cell. Biol., 3, E277-E286.
49. Wiesmuller L. (2001). J. Biomed Biotechnol., 1, 7-10.